BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 15903355)

  • 1. The impact of age on rejection in kidney transplantation.
    de Fijter JW
    Drugs Aging; 2005; 22(5):433-49. PubMed ID: 15903355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased immunogenicity and cause of graft loss of old donor kidneys.
    Fijter JW; Mallat MJK; Doxiadis IIN; Ringers J; Rosendaal FR; Claas FHJ; Paul LC
    J Am Soc Nephrol; 2001 Jul; 12(7):1538-1546. PubMed ID: 11423584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Annual trends and triple therapy--1991-2000.
    Nishikawa K; Terasaki PI
    Clin Transpl; 2001; ():247-69. PubMed ID: 12211788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus: a further update of its use in the management of organ transplantation.
    Scott LJ; McKeage K; Keam SJ; Plosker GL
    Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcineurin inhibitors in pediatric renal transplant recipients.
    Filler G
    Paediatr Drugs; 2007; 9(3):165-74. PubMed ID: 17523697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The UNOS renal transplant registry.
    Cecka JM
    Clin Transpl; 2001; ():1-18. PubMed ID: 12211771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of early cyclosporine levels on kidney allograft rejection.
    Johnson EM; Canafax DM; Gillingham KJ; Humar A; Pandian K; Kerr SR; Najarian JS; Matas AJ
    Clin Transplant; 1997 Dec; 11(6):552-7. PubMed ID: 9408683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
    Nashan B
    Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What has changed in more than 40 years of activity and 3000 kidney transplants at Policlinico University Hospital, Milan.
    Berardinelli L; Raiteri M; Beretta C; Pasciucco A; Giussani A; Carini M; Marenghi C; Rossetti A; Piccolo G
    Clin Transpl; 2011; ():99-110. PubMed ID: 22755406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variable cyclosporine exposure: a risk factor for chronic allograft nephropathy and graft loss?
    He X; Johnston A
    Transplant Proc; 2004 Jun; 36(5):1321-6. PubMed ID: 15251323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients.
    Koziolek MJ; Riess R; Geiger H; Thévenod F; Hauser IA
    Kidney Int; 2001 Jul; 60(1):156-66. PubMed ID: 11422747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of preoperative donor-specific transfusion and cyclosporine in haplo-identical living related renal transplant recipients.
    Sharma RK; Rai PK; Kumar A; Kumar P; Gupta A; Kher V; Agrawal S; Bhandari M
    Nephron; 1997; 75(1):20-4. PubMed ID: 9031265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Kidney transplantation: more kidneys from living donors, individualised immunosuppression and better results].
    van Gelder T; Hesselink DA; Roodnat JI; Ijzermans JN; Weimar W
    Ned Tijdschr Geneeskd; 2003 May; 147(20):955-9. PubMed ID: 12784528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute rejection features in dual kidney transplant recipients from elderly donors: comparison of calcineurin inhibitor-based and calcineurin inhibitor-free immunosuppressive protocols.
    Aiello FB; Furian L; Marino S; Marchini F; Cardillo M; De Fazio N; Rigotti P; Valente M
    Int J Immunopathol Pharmacol; 2009; 22(4):1001-7. PubMed ID: 20074463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppression in live-related donor renal transplantation.
    Iman A; Rao M; Juneja R; Jacob CK
    Natl Med J India; 2001; 14(2):75-80. PubMed ID: 11396322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and structural consequences of early renal allograft injury.
    Baboolal K; Jones GA; Janezic A; Griffiths DR; Jurewicz WA
    Kidney Int; 2002 Feb; 61(2):686-96. PubMed ID: 11849412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression.
    Kandaswamy R; Humar A; Casingal V; Gillingham KJ; Ibrahim H; Matas AJ
    Transplantation; 2007 Mar; 83(6):722-6. PubMed ID: 17414704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The transmission of donor-derived malignant melanoma to a renal allograft recipient.
    Milton CA; Barbara J; Cooper J; Rao M; Russell C; Russ G
    Clin Transplant; 2006; 20(5):547-50. PubMed ID: 16968479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.